List of Figures
Figure 1: Women’s Health Drugs Market, 7MM, Epidemiology Patterns for Endometriosis, 2017–2024
Figure 2: Women’s Health Drugs Market, 7MM, Epidemiology Patterns for Polycystic Ovarian Syndrome, 2017–2024
Figure 3: Women’s Health Drugs Market, 7MM, Epidemiology Patterns for Infertility, 2017–2024
Figure 4: Women’s Health Drugs Market, Global, Key Marketed Products and Approved Indications, 2018
Figure 5: Women’s Health Drugs Market, Global, Annual Revenue for Premarin ($bn), 2006–2024
Figure 6: Women’s Health Drugs Market, Global, Annual Revenue for Lupron ($bn), 2006–2024
Figure 7: Women’s Health Drugs Market, Global, Annual Revenue for Gonal-F ($m), 2017–2024
Figure 8: Women’s Health Market, Global, Annual Revenue for Mirena ($bn), 2006–2024
Figure 9: Women’s Health Drugs Market, Global, Annual Revenue for Celebrex ($bn), 2006–2024
Figure 10: Women’s Health Drugs Market, Global, Annual Revenue for Implanon/Nexplanon ($m), 2007–2024
Figure 11: Women’s Health Drugs Market, Global, Annual Revenue for Yasmin/Yaz ($bn), 2006–2024
Figure 12: Women’s Health Drugs Market, Global, Annual Revenue for Nuvaring ($m), 2006–2024
Figure 13: Women’s Health Drugs Market, Global, Annual Revenue for Gardasil ($bn), 2017–2023
Figure 14: Women’s Health Drugs Market, Global, Annual Revenue for Esmya ($bn), 2013–2024
Figure 15: Women’s Health Drugs Market, Global, Annual Revenue for Orilissa ($bn), 2018–2024
Figure 16: Women’s Health Drugs Market, Global, Overall Pharmaceutical Industry Pipeline by Therapy Area, 2018
Figure 17: Women’s Health Drugs Market, Global, Pipeline by Stage of Development, Molecule Type and Program Type, 2018
Figure 18: Women’s Health Drugs Market, Global, Pipeline for Key Indications by Stage of Development, 2018
Figure 19: Women’s Health Market, Global, Pipeline for Key Indications by Molecule Type, 2018
Figure 20: Women’s Health Drugs Market, Global, Pipeline by Molecular Target, 2018
Figure 21: Women’s Health Drugs Market, Global, Pipeline for Key Indications by Molecular Target Class, 2018
Figure 22: Women’s Health Drugs Market, Global, Clinical Trial Failure Rates by Stage of Development (%), 2006–2018
Figure 23: Women’s Health Drugs Market, Global, Clinical Trial Failure Rates by Stage of Development and Indication (%), 2006–2018
Figure 24: Women’s Health Drugs Market, Global, Clinical Trial Failure Rates by Stage of Development and Molecule Type (%), 2006–2018
Figure 25: Women’s Health Drugs Market, Global, Clinical Trial Failure Rates by Stage of Development and Molecular Target Class (%), 2006–2018
Figure 26: Women’s Health Drugs Market, Global, Clinical Trial Duration by Stage of Development (months), 2006–2018
Figure 27: Women’s Health Drugs Market, Global, Clinical Trial Duration by Stage of Development and Indication (months), 2006–2018
Figure 28: Women’s Health Drugs Market, Global, Clinical Trial Duration by Stage of Development and Molecule Type (months), 2006–2018
Figure 29: Women’s Health Drugs Market, Global, Clinical Trial Duration by Stage of Development and Molecular Target Class (months), 2006–2018
Figure 30: Women’s Health Drugs Market, Global, Clinical Trial Size by Stage of Development (participants), 2006–2018
Figure 31: Women’s Health Drugs Market, Global, Clinical Trial Size by Stage of Development and Indication (participants), 2006–2018
Figure 32: Women’s Health Drugs Market, Global, Clinical Trial Size by Stage of Development and Molecule Type (participants), 2006–2018
Figure 33: Women’s Health Drugs Market, Global, Clinical Trial Size by Stage of Development and Molecular Target (participants), 2006–2018
Figure 34: Women’s Health Drugs Market, Global, Clinical Program Size by Stage of Development (participants), 2006–2018
Figure 35: Women’s Health Drugs Market, Global, Clinical Program Size by Stage of Development and Indication (participants), 2006–2018
Figure 36: Women’s Health Drugs Market, Global, Clinical Program Size by Stage of Development and Molecule Type (participants), 2006–2018
Figure 37: Women’s Health Drugs Market, Global, Clinical Program Size by Stage of Development and Molecular Target (participants), 2006–2018
Figure 38: Women’s Health Drugs Market, Global, Revenue Forecast for Relugolix ($m), 2021–2024
Figure 39: Women’s Health Drugs Market, Global, Annual Revenue Forecast for Bremelanotide ($m), 2019–2024
Figure 40: Women’s Health Drugs Market, Global, Revenue Forecast for SAGE-217 ($m), 2019–2024
Figure 41: Women’s Health Drugs Market, Global, Annual Revenue Forecast for Fezolinetant ($m), 2021–2024
Figure 42: Women’s Health Drugs Market, Global, Revenue Forecast for Zulresso ($m), 2019–2024
Figure 43: Women’s Health Drugs Market, Global, Revenue Forecast for Bizalimogene Ralaplasmid and Mavilimogene Ralaplasmid ($m), 2021–2024
Figure 44: Women’s Health Drugs Market, Global, Revenue Forecast for Retosiban ($m), 2019–2024
Figure 45: Women’s Health Drugs Market, Global, Market Size ($bn), 2017–2024
Figure 46: Women’s Health Drugs Market, Global, Annual Revenue Forecast for Premium and Generic Products ($bn), 2017–2024
Figure 47: Women’s Health Market, Global, Annual Revenue Forecast for G Protein-Coupled Receptor Target Class ($bn), 2017–2024
Figure 48: Women’s Health Drugs Market, Global, Annual Revenue Forecast for Nuclear Receptor Target Class ($bn), 2017–2024
Figure 49: Women’s Health Drugs Market, Global, Annual Revenue Forecast for Pathogen Target Class ($bn), 2017–2024
Figure 50: Women’s Health Drugs Market, Global, Annual Revenue Forecast for Ion Channels/Transporters ($bn), 2017–2024
Figure 51: Women’s Health Drugs Market, Global, Company Analysis Matrix, 2017–2024
Figure 52: Women’s Health Market, Global, Companies by CAGR and Market Share, 2017–2024
Figure 53: Women’s Health Drugs Market, Global, Market Share by Company (%), 2017–2024
Figure 54: Women’s Health Market, Global, Companies by Compound Annual Growth Rate (%), 2017–2024
Figure 55: Women’s Health Market, Global, Revenues by Route of Acquisition, 2017–2024
Figure 56: Women’s Health Drugs Market, Global, Bayer AG Annual Revenue Forecast ($bn), 2017–2024
Figure 57: Women’s Health Market, Global, AbbVie Inc Annual Revenue Forecast ($bn), 2017–2024
Figure 58: Women’s Health Market, Global, Allergan Plc Annual Revenue Forecast ($bn), 2017–2024
Figure 59: Women’s Health Market, Global, Merck& Co. Annual Revenue Forecast ($bn), 2017–2024
Figure 60: Women’s Health Market, Global, GlaxoSmithKline Annual Revenue Forecast ($m), 2016–2023
Figure 61: Women’s Health Market, Global, Pfizer Annual Revenue Forecast ($bn), 2017–2024
Figure 62: Women’s Health Market, Global, TherapeuticsMD Annual Revenue Forecast ($bn), 2017–2024
Figure 63: Women’s Health Drugs Market, Global, High-Activity and Late-Stage Pipeline Developers by Company Type, 2018
Figure 64: Women’s Health Drugs Market, Global, Overall, High-Activity and Late-Stage Developers by Level of Women’s Health Specialization, 2018
Figure 65: Women’s Health Drugs Market, Global, Proportion of Total Company Revenue Attributed to Women’s Health, 2017–2024
Figure 66: Women’s Health Drugs Market, Global, Licensing Deals by Region, Value and Year, 2006–2018
Figure 67: Women’s Health Drugs Market, Global, Licensing Deals by Indication, 2006–2018
Figure 68: Women’s Health Drugs Market, Global, Licensing Deals by Stage of Development and Value, 2006–2018
Figure 69: Women’s Health Drugs Market, Global, Licensing Deals by Molecule Type and Molecular Target, 2006–2018
Figure 70: Women’s Health Drugs Market, Global, Licensing Deals with Disclosed Deal Values (part 1), 2018
Figure 71: Women’s Health Drugs Market, Global, Licensing Deals with Disclosed Deal Values (part 2), 2018
Figure 72: Women’s Health Drugs Market, Global, Co-development Deals by Region, Value and Year, 2006–2018
Figure 73: Women’s Health Drugs Market, Global, Co-development Deals by Indication, 2006–2018
Figure 74: Women’s Health Drugs Market, Global, Co-development Deals by Stage of Development and Value, 2006–2018
Figure 75: Women’s Health Drugs Market, Global, Co-development Deals by Molecule Type and Molecular Target, 2006–2018
Figure 76: Women’s Health Drugs Market, Global, Co-development Deals with Disclosed Deal Values, 2018
Figure 77: Women’s Health Drugs Market, Global, All Pipeline Products, 2018 (part 1)
Figure 78: Women’s Health Drugs Market, Global, All Pipeline Products (part 2), 2018
Figure 79: Women’s Health Drugs Market, Global, All Pipeline Products (part 3), 2018
Figure 80: Women’s Health Drugs Market, Global, All Pipeline Products (part 4), 2018
Figure 81: Women’s Health Drugs Market, Global, All Pipeline Products (part 5), 2018
Figure 82: Women’s Health Drugs Market, Global, All Pipeline Products (part 6), 2018
Figure 83: Women’s Health Drugs Market, Global, All Pipeline Products (part 7), 2018
Figure 84: Women’s Health Drugs Market, Global, All Pipeline Products (part 8), 2018
Figure 85: Women’s Health Drugs Market, Global, All Pipeline Products (part 9), 2018
Figure 86: Women’s Health Drugs Market, Global, All Pipeline Products (part 10), 2018